News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Hot topic
REGULATION
Monthly Recap: China Pharmaceutical Regulatory Updates | November 2021
1. China Insulin VBP Tender Result;
2. NMPA Launches Drug Supply Information Submission System;
3. NMPAs Requires Documentation for Import/Export Permit of Analgesics and Antipsychotics;
4. NMPA Announces One Rx-to-OTC Switch;
5. The 48th Batch of Reference Listed Drugs;
6. NMPA Approves 110 Medical Devices;
7. NHC Releases Administrative Measures for National Essential Medicine List (Revised Draft);
8. NMPA Releases Administrative Measures for Quality Supervision in Drug Supply, Distribution and Use (Consultation Draft)...
Dec 16, 2021
REGULATION
China Cracks Down on Monopolies in Active Pharmaceutical Ingredient Industry
On Nov. 18, China issued the Anti-Monopoly Guidance for Active Pharmaceutical Ingredients, clarifying regulations against monopoly agreements, abuse of market power, and concentration of undertakings in the API industry.
Nov 26, 2021
REGULATION
Monthly Recap: China Pharmaceutical Regulatory Updates | October 2021
China’s Pharma Regulatory Dynamics in Oct. 2021
1. NMPA Releases IVD Reagent Classification Rules
2. NMPA Greenlights 195 Medical Devices
3. NMPA Publishes Medical Device’s Self-Inspection Rules
4. NMPA Rolls Out the 45th, 46th, and 47th Batches of Reference Listed Drugs
5. NHC Consults on Detailed Rules on the Supervision of Internet-based Diagnosis
6. CDE Releases Pharmaceutical Guidelines
Nov 11, 2021
REGULATION
Law & Regulation
Guideline
Marketing Approval
Clinical Trial
Bioequivalence (BE)
Post-market
Drug Registration
New Drug
Monthly Recap: China Pharmaceutical Regulatory Updates | September 2021
1. China's eCTD Format for Drug Marketing Application Dossiers;
2.1. NMPA Underlines Points for Attention on Implementing Administrative Measures for Medical Device Registration and Filing and Administrative Measures for In Vitro Diagnostic Reagent Registration and Filing.
2.2. NMPA Rolls Out the List of Medical Devices Exempted from Clinical Evaluation3 and the List of In Vitro Diagnostic Reagents Exempted from Clinical Trials;
2.3. NMPA Releases Format Requirements for Medical Devices’ or IVD Reagents’ Registration Application Dossiers and Approval Documents;
2.4. Guidelines on Medical Devices and IVD Reagents;
2.5. NMPA Releases Medical Device Industry Standards;
2.6. NMPA, NHC and NHSA Stipulates Unique Device Identifiers;
3. NMPA granted Aloe Vera Pearl Capsules OTC Status;
4.A Collection of Sept. Guidelines Released by NMPA or CDE
Oct 31, 2021
REGULATION
China to Accept eCTD Format for Marketing Authorization Applications for Specific Classes of Drugs
China will start to accept the eCTD format for drug applications on Dec. 29, 2021 while still allowing drug applicants to stay with the current method—submitting compact disks containing dossiers.
Oct 14, 2021
REGULATION
New IVD Reagent Registration and Filing Rules Take Effect in China
1. The Measures’ Application Scope; 2. Definition of IVD Reagents in China; 3. IVD Reagent Classification in China; 4. Definition and Application Scope of IVD Reagent Registration/Filing in China; 5. Qualification of Registration/Filing Applicant and Local Agent;
6. Competent Authority to Submit Application/Documentation to;
7. Documentation for IVD Reagent Registration Application/Filing;
8. Special Approval for IVD Reagents;
9. Product Change and Certificate Validity Extension;
10. Adjusting the Class of Registered IVD Reagents.
Oct 08, 2021
Most Popular
- [Updated] Pharma Licensing Deals Involving Chinese Companies in 2023
- [Updated] Top 10 CROs With the Highest Revenues in 2023
- Decoding China's Good Pharmacovigilance Practices (GVP)
- 2023 China CDE Drug Evaluation Report
- [Updated] China Expedites Process for Transferring Overseas Drug Manufacturing Sites to China